I agree that there is very little compensation fro
Post# of 148186
We are on the outside looking in. We have only been exposed to some of the evidence. Additionally, our company is close to Death's door, with trying to raise enough money, to run a clinical trial, at .14 per share (under .10 for warrants). It is good that we had a very positive outcome, where we got cash and erased some debt. Furthermore, we get our 6.5 million dollar deposit back (I'm pretty sure that we paid Welch back for his loan). Maybe Jay thinks it is better for us to get our drug through a clinical, or two, and that will bring quicker value than an arbitration settlement. I'm with dfwl28, let's move forward. Let's let Leronlimab have a chance, without sabotage, to earn more value like we all imagine it can.